FORWARD PHARMA A/S: Financial statements 2017
CVR: 28865880
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
FORWARD PHARMA A/S (CVR 28865880) has filed annual accounts for 2017. In 2017, the company reported revenue of USD 1,250,000,000 and a net result of USD 880,210,000 compared with USD 2,032,000 the year before. The profit margin was 70.4%. Equity in the 2017 report amounted to USD 89,390,000. The solvency ratio was 51.4%.
- Revenue
- USD 1,250,000,000
- Profit/Loss
- USD 880,210,000
- Equity
- USD 89,390,000
- Total Assets
- USD 173,810,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 1.3 mia. USD | - | 880.2 mio. USD | 89.4 mio. USD | - |
| 2016 | - | - | 2 mio. USD | 189.7 mio. USD | - |
| 2015 | - | - | -51.1 mio. USD | 176.7 mio. USD | - |
| 2014 | - | - | -13.7 mio. USD | 238 mio. USD | - |
| 2012 | - | -11 mio. | 22.4 mio. | 50.4 mio. | - |
Official annual report
Keep an eye on FORWARD PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of July 31, 2017, Rupert Sandbrink has stepped down as director of FORWARD PHARMA A/S.
FORWARD PHARMA A/S has published its annual report for 2016. The net result was DKK 2,032,000.
As of May 3, 2017, Johannes Gerardus Joseph van de Winkel has left the board of directors of FORWARD PHARMA A/S.
As of May 3, 2017, Karen Lesley Smith has left the board of directors of FORWARD PHARMA A/S.
As of April 30, 2017, Joel David Sendek has stepped down as økonomidirektør of FORWARD PHARMA A/S.
As of March 1, 2017, Claus Bo Søndergaard Svendsen is registered as director of FORWARD PHARMA A/S.
As of March 1, 2017, Peder Møller Andersen has stepped down as director of FORWARD PHARMA A/S.
About FORWARD PHARMA A/S
FORWARD PHARMA A/S was a Danish company of the type Aktieselskab based in Hellerup, founded in 2005. The company has been dissolved on 26 November 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company has 4 employees (2018). In 2024, the company reported a gross profit of DKK -9,457,909 and a net result of DKK 75,927,645 compared with DKK -3,832,516 the year before. Equity in the 2024 report amounted to DKK 488,330,233.